GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Credit Rating
With reference to the subject mentioned above, we have to inform you that, CRISIL Ratings has upgraded the credit rating as enclosed.23-12-2021
23-12-2021
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark''s subsidiary, lchnos Sciences and Almirall enter into an exclusive Licensing Agreement for First-In-Class IL-lRAP Antagonist Monoclonal Antibody14-12-2021
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark''s subsidiary, lchnos Sciences and Almirall enter into an exclusive Licensing Agreement for First-In-Class IL-lRAP Antagonist Monoclonal Antibody14-12-2021
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Credit Rating
Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 - S&P Global Ratings. With reference to the subject mentioned above, kindly find enclosed rating research update issued by S&P Global Ratings for your reference.18-11-2021
Accumulate Glenmark Pharmaceuticals target of Rs 575: Geojit
Geojit recommended accumulate rating on Glenmark Pharmaceuticals with a target price of Rs 575 in its research report dated November 18, 2021.18-11-2021
Neutral Glenmark Pharma; target of Rs 560: Motilal Oswal
Motilal Oswal recommended Neutral rating on Glenmark Pharma with a target price of Rs 560 in its research report dated November 15, 2021.16-11-2021
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark Pharmaceuticals makes it to the prestigious Dow Jones Sustainability Emerging Markets Index for the fourth consecutive year16-11-2021
Earnings Call for Q2FY22 of Glenmark Pharmaceuticals Ltd.
Conference Call with Glenmark Pharmaceuticals Management and Analysts on Q2FY22 Performance and Outlook. Listen to the full earnings transcript.15-11-2021
Q2FY22 Quarterly Result Announced for Glenmark Pharmaceuticals Ltd.
Highlights: Glenmark Pharma reports revenue growth of 6.6% and PAT growth of 10.1% YoY for Q2 FY 2021-22 ROW Business grew by 71.5% to Rs. 6,526 Mn Europe Business grew by 6.3% to Rs. 3,383 Mn EBITDA of Rs. 5,902 Mn grew by 6.8% YoY, with margins of 18.8%. For the second quarter of FY 2021-22, Glenmark’s consolidated revenue was at Rs. 31,474 Mn as against Rs. 29,525 Mn recording an increase of 6.6%. Consolidated EBITDA was at Rs. 5,902 Mn in the quarter ended Sept 30, 2021 as against Rs. 5,699 Mn in the previous corresponding quarter, registering an increase of 6.8%. Profit after Tax (PAT)1 was at Rs. 2,577 Mn for the quarter ended Sept 30, 2021 as compared to Rs. 2,340 Mn in the previous corresponding quarter, recording a growth of 10.1%. “We delivered yet another quarter of consistent performance, both in revenue growth and profitability. We have continued to perform well in our core therapy areas and launched differentiated products.” said Glenn Saldanha, Chairman & Managing Director, Glenmark Pharmaceuticals Ltd. He further added, “We have substantially reduced our debt through a combination of internal accruals and IPO proceeds. We are focused on enhancing free cash generation and achieving our strategic objectives going forward." Result PDF15-11-2021
Glenmark Pharma PAT grows 10.1%, revenue grows 6.6% in Sept quarter
Glenmark Pharmaceuticals Limited, a research-led global integrated pharmaceutical company, today announced its financial results for the second quarter ended Sept 30, 2021.For the second quarter of FY 2021-22, Glenmark's consolidated revenue was at Rs 31,474 Mn as against Rs 29,525 Mn recording an increase of 6.6%.Consolidated EBITDA was at Rs 5,902 Mn in the quarter ended Sept 30, 2021 as against Rs 5,699 Mn in the previous corresponding quarter, registering an increase of 6.8%.Profit after Tax (PAT) was at Rs 2,577 Mn for the quarter ended Sept 30, 2021 as compared to Rs 2,340 Mn in the previous corresponding quarter, recording a growth of 10.1%."We delivered yet another quarter of consistent performance, both in revenue growth and profitability. We have continued to perform well in our core therapy areas and launched differentiated products." said Glenn Saldanha, Chairman & Managing Director, Glenmark Pharmaceuticals Ltd.He further added, "We have substantially reduced our...13-11-2021